Type 1 diabetes immunotherapy using polyclonal regulatory T cells
				Jeffrey A. Bluestone			
		
									
					Papers				
 
							
					Science Translational Medicine				
 
					
		
			November 2015		
 
	 Authors and Affiliates
			
				Jeffrey A. Bluestone1, Jane H. Buckner2, Mark Fitch3, Stephen E. Gitelman4, Shipra Gupta2, Marc K. Hellerstein3, Kevan C. Herold5, Angela Lares1, Michael R. Lee1, Kelvin Li6, Weihong Liu1, S. Alice Long2, Lisa M. Masiello1, Vinh Nguyen7, Amy L. Putnam1, Mary Rieck1, Peter H. Sayre8 and Qizhi Tang7
1 Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA. 2 Translational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA. 3 Department of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, CA 94720, USA. 4 Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA. 5 Departments of Immunobiology and Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA. 6 KineMed Inc., Emeryville, CA 94608, USA. 7 Department of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA. 8 Division of Hematology-Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.